Tumor markers in rectal cancer: CEA and its role in monitoring
Tumor markers are substances produced by cancer cells (or by the body in response to cancer) that can be measured in blood. In rectal cancer, the most important tumor marker is CEA (carcinoembryonic antigen). While not perfect, CEA plays an essential role in post-treatment monitoring and in early detection of recurrence.
What CEA is
Definition
CEA (carcinoembryonic antigen) is a protein normally produced in very small amounts by intestinal mucosal cells. In colorectal cancer, tumor cells produce increased amounts of CEA, which reach the blood and can be measured by a simple blood test.
Normal values
- Non-smokers: under 3 ng/mL
- Smokers: under 5 ng/mL (smoking slightly raises CEA)
- Values between 5-10 ng/mL: gray zone — requires further investigation
- Values over 10 ng/mL: strongly suggest cancer (but not diagnostic)
Important limitations
CEA is not a perfect test. It must be understood that:
- It is not a screening test — cannot detect cancer in healthy people
- It is not specific to cancer — can also be elevated in other conditions (see below)
- It is not 100% sensitive — about 30% of colorectal cancers do NOT produce elevated CEA
- It does not replace imaging — a normal CEA does not exclude recurrence
When CEA is measured
Before treatment (at diagnosis)
- Measured at diagnosis, before any treatment
- The initial value serves as a reference for future comparisons
- An initially elevated CEA (above 5 ng/mL) also has prognostic value — suggests a higher risk of recurrence
After surgery
- Measured 4-6 weeks after surgery (after the body has cleared residual CEA)
- If CEA was elevated before surgery and returns to normal afterward — sign that the tumor was completely removed
- If CEA remains elevated after surgery — suggests residual disease (microscopic metastases)
During post-treatment monitoring
Periodic CEA measurement is one of the most important components of monitoring:
| Period | CEA frequency |
|---|---|
| First 2 years | Every 3 months |
| Years 3-5 | Every 6 months |
| After 5 years | Annually (some guidelines recommend stopping) |
During chemotherapy
- CEA may be measured periodically to assess response to chemotherapy
- A drop in CEA suggests the treatment is working
- A rise may indicate disease progression
Interpreting CEA values
Normal and stable CEA
- Good news — suggests no recurrence
- Doesn’t completely rule it out (10-15% of recurrences occur without rising CEA)
- Continue monitoring per the protocol
Progressively rising CEA
A consistent rise in CEA over two or more successive measurements is the most important warning signal:
- Confirm with a second measurement at 2-4 weeks (rule out lab fluctuation)
- Investigate with chest-abdomen-pelvis CT and/or PET-CT
- Evaluate the possibility of locoregional or distant recurrence
Non-cancerous causes of elevated CEA
CEA can also be elevated in situations unrelated to cancer:
- Smoking — the most common cause of falsely elevated CEA
- Liver diseases — cirrhosis, hepatitis
- Inflammatory bowel disease — ulcerative colitis, Crohn’s disease
- Pancreatitis
- Hypothyroidism
- Lung infections — pneumonia
- Stomach ulcer
For this reason, an isolated elevated CEA (a single value) should not cause panic, but must be investigated.
Normal CEA — can I still have recurrence?
Yes. About 30% of colorectal cancers do not produce CEA. If the initial tumor did not produce elevated CEA, monitoring with CEA is less useful. In these cases, imaging (CT, MRI) is essential.
Other tumor markers
CA 19-9
- Another tumor marker sometimes used in colorectal cancer
- Less specific than CEA for colorectal cancer
- Useful as a complementary marker — if CEA is normal, CA 19-9 may be elevated
- Normal values: under 37 U/mL
Microsatellite instability (MSI) and MMR status
- Not blood markers — determined on the tumor sample (biopsy or surgical specimen)
- Enormous importance: MSI-H tumors (high microsatellite instability) respond to immunotherapy
- Tested routinely at diagnosis
- Present in about 15% of colorectal cancers
ctDNA (circulating tumor DNA)
A new and promising tumor marker:
- What it is: fragments of tumor DNA circulating in the blood
- Advantage: extremely sensitive — can detect microscopic residual disease after surgery
- Studies: can identify patients at risk of recurrence even with normal CEA and normal CT
- Limitations: still experimental, not routinely available, high cost
- The future: likely to become the standard of monitoring within 5-10 years
The role of CEA in decision-making
After surgery — adjuvant chemotherapy decision
- A very elevated initial CEA (above 5 ng/mL) may influence the decision to give adjuvant chemotherapy, even at earlier stages
- A CEA that does not normalize after surgery suggests residual disease and the need for systemic treatment
In monitoring — decision to investigate
Typical protocol when CEA rises:
- First rise: repeat the test at 2-4 weeks
- Confirmed rise: chest-abdomen-pelvis CT
- Normal CT but rising CEA: PET-CT (more sensitive for small lesions)
- Identified lesion: multidisciplinary evaluation for treatment
In metastatic disease — monitoring response
- A drop in CEA during chemotherapy confirms treatment response
- A rise in CEA may indicate the need to change the chemotherapy regimen
- CEA usually correlates with tumor volume
Practical tips for patients
Before the test
- No fasting required — CEA can be drawn at any time
- Tell your doctor if you smoke — reference values differ
- Use the same lab — values can vary slightly between labs
- Keep a journal with CEA values — helps visualize the trend
Interpreting results
- Don’t interpret a single isolated result — the trend matters more than the absolute value
- Don’t panic at a slight rise — it may be normal fluctuation
- Discuss with your oncologist — they see the full picture (CEA + imaging + symptoms)
Questions to ask your doctor
- “What was my CEA value at diagnosis?”
- “Did CEA normalize after surgery?”
- “How often should it be measured?”
- “What happens if CEA rises?”
- “Does my tumor produce CEA? (was it elevated at diagnosis?)”
Postoperative monitoring calendar
CEA is part of a complete monitoring program that includes:
| Investigation | First 2 years | Years 3-5 |
|---|---|---|
| CEA | Every 3 months | Every 6 months |
| Chest-abdomen CT | Every 6-12 months | Annually |
| Colonoscopy | At 1 year post-op | At 3 years, then at 5 years |
| Clinical exam | Every 3-6 months | Every 6-12 months |
This article is for informational purposes only and does not replace medical consultation. Discuss with your oncologist about the interpretation of CEA values and your personalized monitoring schedule.